Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.51 |
| ▸ | JAK3 | P52333 | 4/20 | 0.51 |
| ▸ | JAK1 | P23458 | 3/20 | 0.51 |
| ▸ | SRC | P12931 | 13/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | HCK | P08631 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.46 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.46 |
| ▸ | PRKDC | P78527 | 1/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 2/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28370697 | 0.89 | SRC (0.54) | JAK2JAK3SRCEGFRKDR | |
| SCHEMBL14630545 | 0.83 | JAK2 (0.68) | JAK2JAK3JAK1SRCEGFR | |
| SCHEMBL14630543 | 0.83 | JAK2 (0.68) | JAK2JAK3JAK1SRCEGFR | |
| SCHEMBL19476297 | 0.82 | JAK2 (0.66) | JAK2JAK3JAK1SRCEGFR | |
| SCHEMBL22845567 | 0.81 | JAK2 (0.59) | JAK2JAK3JAK1SRCEGFR | |
| SCHEMBL28976279 | 0.81 | JAK2 (0.59) | JAK2JAK3JAK1SRCEGFR | |
| SCHEMBL29763123 | 0.81 | JAK2 (0.59) | JAK2JAK3JAK1SRCEGFR | |
| SCHEMBL19180435 | 0.79 | SRC (0.49) | SRCEGFRKDRPIK3CDABL1 | |
| SCHEMBL19492063 | 0.78 | RET (0.62) | JAK2JAK3JAK1SRCEGFR | |
| SCHEMBL19492064 | 0.78 | RET (0.62) | JAK2JAK3JAK1SRCEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2734529-B1 | BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-09-05 | — | — | EP | disclosed |
| US-9718828-B2 | BTK Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170008899-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20140221333-A1 | BTK INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008899-A1 | BTK INHIBITORS | BTK, SYK, ABL1 | JAK2 8/4885JAK3 19/4885JAK1 10/4885 |
| US-20140221333-A1 | BTK INHIBITORS | BTK, SYK, ABL1 | JAK2 8/4885JAK3 17/4885JAK1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.